Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Agios Pharmaceuticals, Inc.”

93 pharma patents match "Agios Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 93
Index total 30,257
Page 3 / 4

Quick answer

This filtered view shows 93 pharmaceutical patents matching "Agios Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

93 results for “Agios Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 10093654

    Therapeutically active compounds and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Oct 9, 2018 · Expires Oct 4, 2038

    granted
  2. US 10087172

    Compounds and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Oct 2, 2018 · Expires Sep 27, 2038

    granted
  3. US 10087169

    Bicyclic PKM2 activators

    Agios Pharmaceuticals, Inc. · Granted Oct 2, 2018 · Expires Sep 27, 2038

    granted
  4. US 10029987

    Therapeutic compounds and compositions

    Agios Pharmaceuticals, Inc. · Granted Jul 24, 2018 · Expires Jul 19, 2038

    granted
  5. US 10028961

    Therapeutically active compounds and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Jul 24, 2018 · Expires Jul 19, 2038

    granted
  6. US 10017495

    Therapeutically active compounds and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Jul 10, 2018 · Expires Jul 5, 2038

    granted
  7. US 10011574

    Glutaminase inhibitors and method of use

    Agios Pharmaceuticals, Inc. · Granted Jul 3, 2018 · Expires Jun 28, 2038

    granted
  8. US 10000479

    Compounds and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Jun 19, 2018 · Expires Jun 14, 2038

    granted
  9. US 9982309

    Method for treating cell proliferation related disorders

    Agios Pharmaceuticals, Inc. · Granted May 29, 2018 · Expires May 24, 2038

    granted
  10. US 9980961

    Pyruvate kinase activators for use in therapy

    Agios Pharmaceuticals, Inc. · Granted May 29, 2018 · Expires May 24, 2038

    granted
  11. US 9968595

    Pharmaceutical compositions of therapeutically active compounds

    Agios Pharmaceuticals, Inc. · Granted May 15, 2018 · Expires May 10, 2038

    granted
  12. US 9938259

    Therapeutic compositions and related methods of use

    Agios Pharmaceuticals, Inc. · Granted Apr 10, 2018 · Expires Apr 5, 2038

    granted
  13. US 9889137

    Therapeutically active compounds and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Feb 13, 2018 · Expires Feb 8, 2038

    granted
  14. US 9856279

    Therapeutically active compositions and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Jan 2, 2018 · Expires Dec 28, 2037

    granted
  15. US 9850277

    Therapeutically active compositions and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Dec 26, 2017 · Expires Dec 21, 2037

    granted
  16. US 9738625

    Therapeutically active compounds and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Aug 22, 2017 · Expires Aug 17, 2037

    granted
  17. US 9732062

    Therapeutically active compounds and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Aug 15, 2017 · Expires Aug 10, 2037

    granted
  18. US 9724350

    N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer

    Agios Pharmaceuticals, Inc. · Granted Aug 8, 2017 · Expires Aug 3, 2037

    granted
  19. US 9694013

    Therapeutically active compounds and their methods of use

    Agios Pharmaceuticals, Inc. · Granted Jul 4, 2017 · Expires Jun 29, 2037

    granted
  20. US 9682080

    Pyruvate kinase activators for use in therapy

    Agios Pharmaceuticals, Inc. · Granted Jun 20, 2017 · Expires Jun 15, 2037

    granted
  21. US 9662327

    Phenyl and pyridinyl substituted piperidines and piperazines as inhibitors of IDH1 mutants and their use in treating cancer

    Agios Pharmaceuticals, Inc. · Granted May 30, 2017 · Expires May 25, 2037

    granted
  22. US 9657004

    Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use

    Agios Pharmaceuticals, Inc. · Granted May 23, 2017 · Expires May 18, 2037

    granted
  23. US 9656999

    Therapeutically active compounds and their methods of use

    Agios Pharmaceuticals, Inc. · Granted May 23, 2017 · Expires May 18, 2037

    granted
  24. US 9618514

    Methods of evaluating patients using E-cadherin and vimentin

    Agios Pharmaceuticals, Inc. · Granted Apr 11, 2017 · Expires Apr 6, 2037

    granted